TB Online is no longer maintained. This is an archive of the site. For news on TB please go to: https://globaltbcab.org/

Items tagged with Research and development

Documentary on medical research and access to medicines (post)

Salud por Derecho produced a documentary on medical research and access to medicines. Health experts and opinion leaders from around the world speak about the current system of research, development and innovation of drugs. 

WHO publishes list of bacteria for which new antibiotics are urgently needed (post)

27 February 2017 | GENEVA WHO today published its first ever list of antibiotic-resistant "priority pathogens" – a catalogue of 12 families of bacteria that pose the greatest threat to human health.

WHO stresses urgent need for R&D for drug-resistant TB alongside newly-prioritized antibiotic-resistant pathogens (post)

28 February 2017 | GENEVA - WHO reaffirms the critical need for research and development (R&D) of new antibiotics to tackle the threat of drug-resistant tuberculosis (TB).

WHO Advisory Group report on Fair Pricing Forum released (post)

The report from a meeting of a World Health Organization informal advisory group on challenges of medicines pricing and organising a Fair Pricing Forum this spring has been made public. The report shows the analysis and assertions of the diverse group, as well as questions and plans to take forward.

TB and antimicrobial resistance – new models of R&D needed (post)

An editorial published in the Bulletin of the World Health Organization reflects on the need for new models of research and development (R&D) for TB and antimicrobial resistance and describes a new funding framework called the 3P Project.

G20: Can the world’s richest economies innovate for global health? (post)

The term “neglected tropical diseases” is on the way out.

WHO, stakeholders take ‘first step’ on fair pricing for medicines (post)

The World Health Organization has concluded a major one-day forum on fair pricing of medicines, bringing a wide range of stakeholders together in Amsterdam and coming up with several possible actions for the way ahead. Key points of discussion included a definition of fair pricing, moving away from value-based pricing, delinkage of price from research and development costs, and greater transparency, according to participants.

WHO studies on local pharma production provide key contrasts between China, India (post)

Two new studies published by the World Health Organization provide insight on the production of pharmaceutical products in India and China. According to the studies, China has a substantial local pharmaceutical manufacturing sector which the Chinese government is closely linking to its policy objective of universal health care. India, the main global provider of generic medicines is not pursuing a comparable focus on universal health care. India is increasingly faced with Chinese pharmaceutical sector competition, with China being its main provider of commoditized active pharmaceutical ingredients (APIs).

Antimicrobial resistance needs new R&D models, NGOs say (post)

A group of non-governmental organisations organised a side event to the World Health Assembly to discuss the growing issue of antimicrobial resistance, the way to incentivise research and development for new antibiotics, and the imperative of affordability and accessibility of new products. The speakers mentioned alternative models, such as delinking the cost of research from the price of the medicines, underlined the high prices of vaccines, and the importance of systems of infection prevention and control.

GHIT Fund secures commitments of over US$200 million to its replenishment for the acceleration of Japanese innovation for infectious diseases of the developing world (post)

This announcement demonstrates the continued leadership and commitment of the Government of Japan, leading life sciences companies, international foundations and other partners to combat neglected diseases; with this replenishment, which marks a doubling of previous commitments, GHIT will accelerate and expand its development of new tools while ensuring they are accessible and delivered to the world’s most vulnerable.

Page 7 of 28 · Total posts: 0

←First 6 7 8 Last→